Hongene Biotech has announced it has received a grant from the Gates Foundation to develop high-quality, affordable, and patent-free cap analogs critical for mRNA vaccine production. The initiative aims to strengthen global vaccine supply chains and expand equitable access for low- and middle-income countries (LMICs). 

Under the grant, Hongene will focus on developing and scaling production of key capping reagents—essential components of mRNA therapeutics—emphasizing accessibility, transparency, and global deployment. Technologies and knowledge generated through the project will be made widely available at affordable pricing, addressing public health needs in LMICs. 

“High-quality raw materials are foundational to the reliability and scalability of mRNA manufacturing,” said David Butler, Chief Technology Officer at Hongene. “This grant enables us to contribute our deep expertise in nucleotide chemistry to a global effort aimed at strengthening vaccine equity and readiness.” 

The agreement includes provisions for open dissemination of results and technologies, reflecting Hongene’s commitment to materials that meet strict quality standards without restrictive intellectual property barriers. 

The project aligns with the Gates Foundation’s Global Access principles, including licensing measures to ensure developments and essential background technology are available to public sector and nonprofit manufacturers working to expand vaccine access in LMICs.